# US 2003/0212043 A1 · Cyclodextrin-drospirenone inclusion complexes

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0212043 A1
- Document ID: US20030212043A1
- Status: Published application
- Kind: A1
- Application number: 10/464,453
- Filed: 2003-06-19
- Published: 2003-11-13
- Earliest claimed: 2000-12-20
- Assignees: Schering Corporation
- Inventors: Thomas Backensfeld; Wolfgang Heil
- Web page: https://patentgrep.com/patent/US20030212043A1

## CPC

- A61K 47/6951: {using cyclodextrin (cyclodextrins used as simple excipients A61K47/40)}
- A61K 31/585: containing lactone rings, e.g. oxandrolone, bufalin
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 15/12: for climacteric disorders
- A61P 15/18: Feminine contraceptives
- B82Y 5/00: Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
- C08B 37/0015: {Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- B82Y: SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- C08B: POLYSACCHARIDES; DERIVATIVES THEREOF (polysaccharides containing less than six saccharide radicals attached to each other by glycosidic linkages C07H; fermentation or enzyme-using processes C12P19/00; sugar industry C13; production of cellulose D21)

## Abstract

Described are inclusion complexes formed between cyclodextrin and drospirenone. In a specific embodiment of the invention, the cyclodextrin is β-cyclodextrin. The invention further relates to methods of providing such an inclusion complex, and to the use of said inclusion complex for improving the solubility of drospirenone, for providing pharmaceutical compositions, for use as a medicament in the treatment of symptoms associated with menopause and in female contraception.

## Claims

### Claim 1

An inclusion complex between cyclodextrin and drospirenone.

### Claim 2 (depends on 1)

The inclusion complex according to claim 1, wherein the cyclodextrin is selected from the group consisting of α-cyclodextrin, β-cyclodextrin, γ-cyclodextrin and derivatives thereof.

### Claim 3 (depends on 2)

The inclusion complex according to claim 2, wherein the cyclodextrin is β-cyclodextrin or γ-cyclodextrin.

### Claim 4 (depends on 3)

The inclusion complex according to claim 3, wherein the cyclodextrin is β-cyclodextrin.

### Claim 5 (depends on 1)

The inclusion complex according to claim 1, wherein the inclusion complex between drospirenone and the cyclodextrin is in a molar ratio, respectively, selected from the group consisting of 1:1, 2:1, 3:1, 3:2, 1:2, 2:2, 2:3 or 1:3.

### Claim 6 (depends on 5)

The inclusion complex according to claim 5, wherein the ratio is 1:1, 2:1 or 1:2.

### Claim 7 (depends on 1)

The inclusion complex according to claim 1 further comprising one or more therapeutically active substances.

### Claim 8 (depends on 1)

A method for producing an inclusion complex of claim 1 comprising combining cyclodextrin and drospirenone at a molar ratio of, respectively, from 0.3:1 to 20:1.

### Claim 9 (depends on 8)

The method of claim 8, wherein the ratio is 1:1, 2:1, 3:1, 4:1 or 5:1.

### Claim 10 (depends on 8)

The method of claim 8, wherein the ratio is 2:1 or 3:1.

### Claim 11 (depends on 8)

The method according to claim 8, comprising the combining of a solution of drospirenone with a solution of cyclodextrin.

### Claim 12 (depends on 8)

The method according to claim 8, comprising the combining of solid drospirenone with a solution of cyclodextrin.

### Claim 13 (depends on 8)

The method according to claim 8, wherein the cyclodextrin is in solution comprising a solvent selected from the group consisting of water, ethanol, acetone, acetonitrile, methanol, DMSO, pyridine or combinations thereof.

### Claim 14 (depends on 13)

The method of claim 13, wherein the solution comprises water.

### Claim 15

The method according to 8, wherein the drospirenone is in solution comprising a solvent selected from the group consisting of water, ethanol, acetone, acetonitrile, methanol, DMSO, pyridine or combinations thereof.

### Claim 16 (depends on 15)

The method of claim 15, wherein the solution comprises water, ethanol or both.

### Claim 17 (depends on 8)

The method according to claim 8 comprising;
dissolving cyclodextrin in water, optionally with heating, to form a cyclodextrin solution;
dissolving drospirenone in a solvent selected from the group consisting of water and ethanol or mixtures thereof, optionally with heating, to form a drospirenone solution;
combining the cyclodextrin solution and the drospirenone solution to form a combined solution;
stirring the combined solution;
filtering the resultant precipitate;
washing the precipitate with a solvent selected from the group consisting of water, ethanol, ether and acetone, preferably wherein the solvent is cooled to below 25° C.;
optionally suspending the resultant solid in a solvent and washing the suspended material with a solvent selected from the group consisting of water, ethanol, ether and acetone;
removing substantially all of the solvent from the resultant or suspended material.

### Claim 18 (depends on 17)

The method according to claim 17, wherein the removing of solvent is by spray drying.

### Claim 19 (depends on 17)

The method according to claim 17, wherein the removing of solvent is by lyophilization.

### Claim 20 (depends on 8)

The method according to claim 8 further comprising combining a therapeutically active substance to a combined solution of drospirenone, to a drospirenone solution, or to a cyclodextrin solution.

### Claim 21

A method for improving the solubility of drospirenone in water comprising complexing drospirenone with cyclodextrin to form an inclusion complex.

### Claim 22 (depends on 1)

A pharmaceutical composition comprising an inclusion complex of drospirenone and cyclodextrin as defined by claim 1 together with one or more pharmaceutically acceptable carriers or excipients.

### Claim 23 (depends on 22)

The pharmaceutical composition according to claim 22 adapted to be administered by oral, parenteral, mucosal, topical, vaginal, subcutaneous or nasal administration.

### Claim 24 (depends on 22)

The pharmaceutical composition according to claim 22, wherein the amount of drospirenone is from approximately 0.1 mg to 10 mg.

### Claim 25 (depends on 22)

The pharmaceutical composition according to claim 22 further comprising one or more therapeutically active substances.

### Claim 26 (depends on 1)

Use of the inclusion complex as defined by claim 1 as a medicament.

### Claim 27 (depends on 1)

A method for female contraception comprising administering an inclusion complex as defined by claim 1 to a female.

### Claim 28 (depends on 1)

A method for treating menopausal symptoms comprising administering an inclusion complex as defined by claim 1 to a female.
